Jiangsu wuzhong(SH:600200) Zheng Quan Zhi Xing·2025-08-26 10:24Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of forced delisting due to major violations and financial issues, including false reporting of revenue and profits from 2020 to 2023 [4]. Group 1: Major Violation Delisting Risk - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for falsely inflating operating income, costs, and profits, which may lead to forced delisting [4]. - The company’s stock has been under risk warning since July 14, 2025, due to the potential for major violations leading to termination of listing [1][4]. Group 2: Financial Delisting Risk - The 2024 financial report received a disclaimer of opinion from the auditing firm, triggering financial delisting risks under the Shanghai Stock Exchange rules [1][2]. - The company is currently under risk warning due to financial issues, including the inability to express an opinion on internal controls [2]. Group 3: Other Risk Warnings - The company is facing additional risk warnings due to non-operational fund occupation by related parties, which violates stock exchange regulations [2]. - The company has also encountered operational risks, including a contract termination with a medical product distributor, affecting sales [2]. Group 4: Investor Advisory - The company urges investors to be cautious and rational in their investment decisions, especially given the recent abnormal stock price fluctuations that do not align with deteriorating fundamentals [4].